Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Efficacy of ELAPR in Women With Striae Distensae Alba

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02510768
Recruitment Status : Completed
First Posted : July 29, 2015
Last Update Posted : July 2, 2018
Sponsor:
Information provided by (Responsible Party):
Elastagen Pty Ltd

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The study is designed to evaluate the efficacy of two formulations of a cross-linked tropoelastin matrix given the product codes ELAPR002f and ELAPR002g (collectively referred to as ELAPR or ELAPR002) for the treatment of Striae Distensae (SD) alba when administered as intradermal implants.

Condition or disease Intervention/treatment Phase
Striae Distensae Device: ELAPR002f Device: ELAPR002g Device: Saline Phase 1

Detailed Description:
The study will consist of six study visits. There will be a screening visit to confirm eligibility and to assess baseline parameters (Day -28 to Day -1). For enrolled subjects there will be three intradermal (i.d.) treatment sessions of ELAPR002f or ELAPR002g and placebo, given at one-monthly intervals (approximately Day 0, Day 28 and Day 56). There will be a safety assessment visit 7 days after the first treatment session (Day 7) to review any adverse events and assess the implant sites. ELAPR002f or ELAPR002g will be administered alone vs. placebo. Subjects will be followed for a total of 12 weeks (to Day 84) following the first treatment, with efficacy and safety assessments undertaken at each study visit. At the final follow-up visit (Day 84) a biopsy sample will be taken from each of the treated SDs (active and placebo treated), together with a control biopsy of normal skin collected from an area of the lateral aspect of the abdomen, hip or thigh without an SD alba. Each study subject will act as their own control with active and placebo treatments given single-blind to contralateral sides of the abdomen, hip or thigh, into matched and paired SD. Prior to administration the selected injection sites along the length of SD alba to be treated will be identified and marked with a semi-permanent mark to ensure consistency of anatomic sites for treatment and biopsy. Follow-up period extended to D168, D336 and D504.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Within-Subject, Placebo-Controlled, Single-Blind Study to Evaluate the Efficacy of ELAPR002f and ELAPR002g in Women With Striae Distensae (SD) Alba
Actual Study Start Date : April 16, 2015
Actual Primary Completion Date : October 3, 2017
Actual Study Completion Date : March 6, 2018
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: ELAPR002f
ELAPR002f A tropoelastin polymer cross-linked with hyaluronic acid.
 Device: ELAPR002f
Intradermal implant
Experimental: ELAPR002g
ELAPR002g A tropoelastin polymer cross-linked with hyaluronic acid.
 Device: ELAPR002g
Intradermal implant
Placebo Comparator: Saline
Saline
 Device: Saline
Intradermal implant


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Size of SD alba scars pre and post treatment. [ Time Frame: 3 months ]
    Measurement of scar dimensions pre and post treatment (width x length x depth in mm) as measured by 3D photography, also 2D photography, subject satisfaction and biopsy (histology).


Secondary Outcome Measures :
  1. Frequency and severity of implant site reactions post treatment. [ Time Frame: 3 months ]
    Measure incidence and severity of implant site reactions as assessed by clinical observation and subject diary card records.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Female subjects with at least four abdominal, hip or thigh SD alba which are approximately bilaterally symmetrical (similar dimensions/location/colour) and are of at least 6 cm in length and no more than 5mm wide.
  • SD alba within an area of skin of otherwise normal, smooth, mainly flat appearance.
  • Age: 30 - 55 years.
  • BMI: 18.5 to 35.0 Kg/m2.
  • Capable of providing voluntary informed consent.
  • Good general health.
  • Female subjects who are sexually active will be of non-child bearing potential (i.e., surgically sterilized or postmenopausal), abstain from sexual intercourse, or use a reliable method of contraception (e.g. hormonal contraceptive, condom, IUD) for at least 30 days prior to dosing and during the duration of the study.
  • Fitzpatrick skin types II, III or IV.

Exclusion Criteria:

  • SD alba within an area of otherwise abnormal skin appearance including unusual lumpiness or abnormal skin laxity.
  • Current or previous medical or surgical treatment of SD.
  • Known hypersensitivity to tropoelastin, hyaluronic acid or any other component of ELAPR002f or ELAPR002g.
  • Female subjects with a positive pregnancy test, women refusing to agree to adequate contraception and pregnancy tests during the study, or women who are planning to become pregnant during the period of the trial.
  • Participation in a clinical trial of a pharmacological agent within 1 month prior to screening.
  • Clinically significant haematology or biochemistry findings at screening.
  • Positive test for hepatitis B, hepatitis C or HIV at screening.
  • Bleeding diathesis, anticoagulant drugs, thrombocytopenia or clinically significant prolonged activated partial thromboplastin time (APTT) or prothrombin time (PT).
  • Chronic use of aspirin, other non-steroidal anti-inflammatory drugs or other anti-platelet agents.
  • History of keloid formation.
  • Systemic corticosteroids within last 12 weeks.
  • Diabetes or other metabolic disorders that may interfere with the subject's response to treatment in the opinion of the investigator.
  • Any serious medical condition which in the opinion of the investigator would have a strong possibility of requiring systemic corticosteroid medication.
  • Females who are pregnant or lactating.
  • Previous administration of tropoelastin.
  • A history of anaphylaxis or allergic reactions including any known hypersensitivity to lidocaine.
  • Use of any investigational product on the intended implant site in the previous 12 months.
  • Fitzpatrick skin types I, V or VI.
  • Any other factor that in the opinion of the Investigator would make the subject unsafe or unsuitable for the study.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02510768


Locations
Layout table for location information
United Kingdom
Hammersmith Medicines Research
London, United Kingdom, NW10 7EW
Sponsors and Collaborators
Elastagen Pty Ltd
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Elastagen Pty Ltd
ClinicalTrials.gov Identifier: NCT02510768    
Other Study ID Numbers: ELAPR-P1C
First Posted: July 29, 2015    Key Record Dates
Last Update Posted: July 2, 2018
Last Verified: June 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Elastagen Pty Ltd:
alba
Additional relevant MeSH terms:
Layout table for MeSH terms
Striae Distensae
Skin Manifestations